ABD
Triple-Negative Breast Cancer (TNBC), Head and Neck Squamous Cell Carcinoma (HNSCC)
Non-ClinicalIn development (Fully-Owned, In-License)
Key Facts
Indication
Triple-Negative Breast Cancer (TNBC), Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase
Non-Clinical
Status
In development (Fully-Owned, In-License)
Company
About ARTBIO
ARTBIO is pioneering a holistic approach to Alpha Radioligand Therapy (ART), combining a differentiated pipeline with proprietary isotope production and manufacturing capabilities. Founded in 2021 by the inventors of the first-ever metabolically targeted alpha therapy (Xofigo), the company is advancing multiple programs, with its lead candidate AB001 now in Phase 1/2 clinical trials for prostate cancer. Backed by a strong syndicate of top-tier life science investors, ARTBIO aims to unlock the superior efficacy and safety profile of alpha-emitting radioligands to treat a range of solid tumors.
View full company profile